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http://dx.doi.org/10.1016/j.ccr.2012.07.016SUMMARYAcquired resistance to Docetaxel precedes fatality in hormone-refractory prostate cancer (HRPC). However,
strategies that target Docetaxel resistant cells remain elusive. Using in vitro and in vivo models, we identified
a subpopulation of cells that survive Docetaxel exposure. This subpopulation lacks differentiation markers
and HLA class I (HLAI) antigens, while overexpressing the Notch and Hedgehog signaling pathways. These
cells were found in prostate cancer tissues and were related to tumor aggressiveness and poor patient prog-
nosis. Notably, targeting Notch and Hedgehog signaling depleted this population through inhibition of the
survival molecules AKT and Bcl-2, suggesting a therapeutic strategy for abrogating Docetaxel resistance
in HRPC. Finally, these cells exhibited potent tumor-initiating capacity, establishing a link between chemo-
therapy resistance and tumor progression.INTRODUCTION
Prostate cancer is the most common cancer diagnosis and
second leading cause of cancer-related death in men (Jemal
et al., 2011). Despite the availability of local treatment, many
patients relapse after primary therapy. Initially, relapsed prostate
cancer patients have a hormone-dependent disease that re-
sponds to androgen withdrawal. However, despite hormonal
manipulations prostate cancer progresses to a hormone refrac-
tory state (Pound et al., 1999). Docetaxel is a taxane antimitotic
agent currently used as the standard therapy for patients with
hormone-refractory prostate cancer (HRPC) (Petrylak et al.,Significance
Acquisition of chemotherapy resistance is a devastating an
Docetaxel improves survival in HRPC, patients who initially resp
stalemate and death. This study identified a subpopulation of p
The molecular characterization of this subpopulation culminat
Docetaxel with Notch and Hedgehog inhibitors abrogated the
the rationale for a therapeutic strategy in a currently intractab
Can2004; Tannock et al., 2004). However, patients treated with
this agent inexorably experience disease progression, and
because limited effective therapies exist in this context,
acquired resistance to Docetaxel is commonly fatal. Presently,
the main identified mechanisms of acquired resistance relate
to the expression of b-tubulin isoforms/mutations and the
activation of drug efflux pumps, among others (Mahon et al.,
2011; Seruga et al., 2011). Unfortunately, in spite of these
advances, treatment of Docetaxel-resistant patients remains
a critical clinical challenge. In this study, we sought to identify
a therapeutic strategy to abrogate acquired resistance to Doce-
taxel in HRPC.d widespread phenomenon in clinical oncology. Although
ond acquire resistance, and this event precedes therapeutic
rostate cancer cells that contribute to Docetaxel resistance.
ed in an in vivo model in which a combination strategy using
acquisition of Docetaxel resistance. These findings provide
le clinical challenge.
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Docetaxel-Resistant Prostate Cancer Cells Lack
Differentiation Markers and Show Upregulation of the
Notch and Hedgehog Signaling Pathways
To study the phenomenon of relapse following Docetaxel
therapy, we generated in vitro chemoresistance models using
the well-established HRPC cell lines DU145 and 22Rv1. Drug-
resistant cells were established by exposure to increasing
concentrations of Docetaxel, and resistance was validated by
cell viability, colony formation, annexin V, and poly-(ADP-ribose)
polymerase (PARP) cleavage assays (Figures S1A–S1D available
online). Gene expression profiling using oligonucleotide microar-
rays was performed to compare the sensitive parental cells
(DU145/22Rv1) with the Docetaxel-resistant cells (DU145-DR/
22Rv1-DR). This analysis revealed 1,245 deregulated genes in
DU145-DR and 990 deregulated genes in 22Rv1-DR, of which
247 overlapped (Figure 1A). Of these overlapping genes,
29.5% were consistently upregulated and 70.5% were consis-
tently downregulated. Gene Ontology (GO) analysis of these
247 genes revealed that, besides expected changes in biologi-
cal processes, such as cell proliferation, cell death, and drug
response, other categories, including cell differentiation, antigen
presentation, and developmental/stemness pathways were sig-
nificantly represented (Figure 1B).
Regarding differentiation, we focused on the expression of the
low molecular weight cytokeratins (CKs) 18 and 19, because
these epithelial markers are specifically expressed in normal
luminal human prostate cells and prostate cancer (Ali and Ep-
stein, 2008). We also analyzed prostate-related biomarkers,
including the androgen receptor (AR), prostate-specific antigen
(PSA), and prostate-specific membrane antigen (PSMA). We
observed that DU145-DR and 22Rv1-DR showed a dramatic
decrease in mRNA (Figure 1C) and protein levels of CK18 and
CK19 (Figures 1D and 1E). 22Rv1, which expresses prostate-
related differentiation markers, showed a decrease in mRNA
and protein levels of PSMA and PSA, as well as a decrease in
AR protein expression in Docetaxel-resistant cells (Figure 1D).
Because loss of luminal markers could indicate a possible
shift to a basal phenotype, we analyzed the expression of high
molecular weight CKs and the prostate basal markers CD44
and p63. Highmolecular weight CKs (CK5 andCK14) and p63 re-
mained undetectable in the drug-resistant cells as well as in their
respective parental cells (Figures 1C and 1D). CD44 mRNA and
protein levels were increased in DU145-DR and decreased in
22RV1-DR relative to their parental lines, indicating a cell line-
dependent effect (Figures 1C and 1D). Therefore, the decrease
in luminal differentiation and prostate-specific markers was not
associated with a consistent shift to a basal phenotype. Further,
Docetaxel-resistant cells did not express other lineage markers
(Figure S1E). Finally, Docetaxel-resistant cells showed a strong
downregulation of the mRNA level of HLAI antigens A, B, C, E,
F, and G (Figure 1C), which was confirmed with a pan-HLAI anti-
body by immunoblotting (Figure 1D) and immunofluorescence
(Figure 1E).
Regarding the developmental/stemness category, we ob-
served that Docetaxel-resistant cells showed a marked upregu-
lation of the Notch and Hedgehog signaling pathways. There
was increased NOTCH2 and HES1 mRNA levels (Figure 1C),374 Cancer Cell 22, 373–388, September 11, 2012 ª2012 Elsevier Inwhich was associated with increased cleaved Notch2 and
Hes1 protein expression (Figure 1D) and cleaved Notch2 locali-
zation within the nucleus, where it exerts its activity (Figure 1E).
Moreover, resistant cells showed reduced expression of the
Hedgehog receptor Patched, which normally inhibits the activity
of Smo, a positive regulator of the Hedgehog pathway (Figures
1C and 1D). This was associated with increased protein levels
and nuclear localization of the transcription factors Gli1 and
Gli2 (Figures 1D and 1E), consistent with Hedgehog pathway
activation. In summary, Docetaxel-resistant HRPC cells dis-
played a phenotype characterized by loss of epithelial dif-
ferentiation markers, prostate-specific antigens, and antigen
presentation molecules, as well as an increase in the Notch
and Hedgehog developmental signaling pathways.
Primary and Metastatic Prostate Cancer Tissues
Contain Cells that Display the Docetaxel Resistance
Phenotype and Associate with Tumor Aggressiveness
We next investigated whether cells with the identified Docetaxel-
resistant phenotype were detectable in human prostate cancer
tissue samples. We analyzed paraffin embedded tissues from
31 untreated primary prostate tumors from patients who had
undergone radical prostatectomy and 36 metastatic prostate
cancer tissue samples from untreated or Docetaxel-treated
patients. Immunofluorescence-based double staining revealed
that all prostate cancer tumors had a small subpopulation of
CK-negative (CK) tumor cells that displayed the Docetaxel-
resistant phenotype observed in our in vitro models. CK18/
CK19 cells were mainly HLAI-negative (HLAI) (98.5% ±
1.1%) and displayed nuclear expression of cleaved Notch2
(72.8% ± 15.1%), Gli1 (67.5% ± 17.3%) and Gli2 (67% ±
17.3%), whereas CK-positive (CK+) cells were HLAI-positive
(HLAI+, 99.6% ± 0.3%) and showed significantly lower nuclear
expression of developmental transcription factors (p < 0.0001,
Figure 2A). Moreover, CK tumor cells lacked expression of
nuclear AR, whereas CK+ cells displayed nuclear AR in
71.8% ± 14.3% of the cells (p < 0.0001; Figure 2B). Further,
CK cells did not express high molecular weight CK5 and
CK14, or p63 (Figure S2A). Finally, CK cells did not exhibit
morphological criteria of necrosis (Figure S2B), and a subset ex-
pressed the proliferative marker Ki67 (Figure S2C).
Quantitative analysis revealed that in 31 primary tumors CK
cells accounted for a mean of 1.3% ± 0.94% of the total tumor
cell population, whereas in the 36 metastatic prostate tissues
this cell population accounted for 3.2% ± 2.2% (Table S1).
Therefore, specimens from advanced disease exhibited a higher
percentage of CK cells (p < 0.0001). Notably, 14 out of the 36
metastatic prostate cancer samples analyzed belonged to
patients who had been previously treated with Docetaxel and
had the highest percentage of CK cells (5.2% ± 2.1%), whereas
tumors of the other 22 untreated patients had a lower percentage
of CK cells (1.8% ± 1.4%; p < 0.0001; Figure 2C). Thus, cells
with the Docetaxel-resistant phenotype were more abundant in
metastatic tumors and after chemotherapy treatment.
Next, we investigated if this subpopulation had prognostic
significance in primary prostate cancer. Quantitative analysis
performed in the 31 primary prostate tumor samples showed
that the percentage of the CK cells was significantly related
to established clinicopathologic prognostic factors like tumorc.
Figure 1. Phenotypical Characterization of Docetaxel-Resistant Cells
(A) Genes with at least 1.8-fold increase ([) or decrease (Y) in transcript expression comparing parental and Docetaxel-resistant cells.
(B) Gene ontology categories of overlapping genes. Categories with statistical significance (p% 0.01) are represented. *GO categories related to cell proliferation,
cell death, and response to drugs. **GO categories related to developmental processes. ***GO category related to antigen presentation.
(C) Heatmap illustrates epithelial differentiation, prostate specific, HLAI, and developmental (Notch and Hedgehog) gene expression of parental and Docetaxel-
resistant cells.
(D) Immunoblotting and quantification of parental and Docetaxel-resistant cells for indicated proteins. SCaBER was used as a positive control for high molecular
weight cytokeratins and p63.
(E) Immunofluorescent staining of parental and Docetaxel-resistant cells for indicated proteins.
See also Figure S1.
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Figure 2. Docetaxel-Resistant Cells Are Present in Prostate Cancer Tissue Samples and Associate with Tumor Aggressiveness
(A and B) Hematoxylin and eosin (H&E) and immunofluorescent staining analyses of prostate cancermetastases for indicated proteins.White arrows point to CK
cells. Corresponding box plots show protein expression in CK and CK+ cells, including (from top) upper outliers, maximum (excluding outliers), upper quartile,
median, lower quartile, minimum (excluding outliers), and lower outliers.
(C) CK18 and CK19 immunohistochemistry of clinical metastatic prostate cancer tissues nontreated and treated with Docetaxel.
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ure 2D). Further, patients with a high percentage of CK cells
had a shorter time to biochemical (PSA) relapse than did patients
with a low percentage of CKcells (p < 0.0001; Figure 2E). In
summary, cells displaying the Docetaxel-resistance phenotype
were detectable in primary and metastatic prostate cancer
tissue samples, increased in number after chemotherapy, and
their abundance was associated with tumor aggressiveness
and clinical prognosis.
A Subpopulation of Prostate Cancer Cells Exhibits the
Docetaxel Resistance Phenotype and Survives
Docetaxel Exposure
We next investigated whether the changes observed during the
acquisition of Docetaxel resistance were the result of transition
of sensitive cells toward a resistant phenotype or if chemo-
therapy had selected for a subpopulation of intrinsically Doce-
taxel-resistant cells (Figure 3A). Because both DU145-DR and
22Rv1-DR cells displayed downregulation of CK19 and CK18,
we chose these markers to determine if CK cells were present
in the parental cell lines before any treatment. Immunofluores-
cence and flow cytometry revealed a small CK subpopulation
in both DU145 and 22Rv1 parental cells (Figure 3B).
We next investigated if this subpopulation could contribute to
the acquisition of Docetaxel resistance. To test this hypothesis
we designed a strategy to track the behavior of CK cells under
chemotherapy. We cloned a region of the CK19 promoter into
a GFP vector, creating a reporter system for the expression of
CK19 under different experimental conditions (Tripathi et al.,
2005). DU145 and 22Rv1 parental cells were transfected with
the pCK19-GFP construct and selected to establish stable cell
lines named DU145-pCK19-GFP and 22Rv1-pCK19-GFP. Co-
expression of CK19 and GFP was validated by immunofluores-
cence (Figure S3A), and PCR confirmed stable integration of
the construct (data not shown).
We then tested whether CK19/GFP cells survived Docetaxel
exposure and were responsible for acquired chemoresistance
(Figure 3C). Analysis of DU145-pCK19-GFP cells by flow cytom-
etry showed that CK19/GFP+ cells were a majority (87.5% ±
10.4%) of the total population before any treatment. However,
the viable CK19/GFP+ population was reduced to 28.3% ±
10.6% after exposure to 10 nM Docetaxel for 72 hr. In con-
trast, the viable CK19/GFP population increased from 4.4% ±
4.3% to 73.1% ± 10.2%. Similar results were observed in
22Rv1-pCK19-GFP cells after exposure to 50 nM Docetaxel,
with viable CK19/GFP cells increasing from 8.5% ± 3.5% to
78.6% ± 4.1%, whereas viable CK19/GFP+ cells decreased
from 85.0% ± 2.0% to 19.3% ± 3.4%. Further, colony formation
assays showed that only CK19/GFP cells formed colonies after
exposure to Docetaxel (Figure 3D). Next, we analyzed the
behavior of DU145-pCK19-GFP and 22Rv1-pCK19-GFP in the
presence of Docetaxel by live imaging. We observed that
CK19/GFP cells were able to divide and exit mitosis under
therapy, whereas CK19/GFP+ cells died after mitotic arrest (Fig-(D) Association between the percentage of CK cells with Gleason Score and pa
(E) Kaplan-Meier analysis of biochemical recurrence free survival of primary pros
CK content (>1.3%). Representative samples with low and high percentage of C
See also Figure S2 and Table S1.
Canure 3E; Figure S3B; Movies S1 and S2). Finally, we characterized
the CK19/GFP and CK19/GFP+ populations of DU145-pCK19-
GFP and 22Rv1-pCK19-GFP, both under control and Docetaxel-
treated conditions (Figure 3F). Immunoblots confirmed that
CK19/GFP cells exhibited the Docetaxel-resistance markers,
namely, reduced CK18, CK19, HLAI, Patched, AR, PSMA, and
PSA expression, as well as upregulation of cleaved Notch2,
Hes1, Gli1, and Gli2. Moreover, unsorted cells treated with
Docetaxel underwent the expected reduction in differentiation
markers and an increase in developmental signaling pathways.
We also observed that CK19/GFP cells exhibited a multidrug
resistance phenotype. Indeed, CK19/GFP cells from DU145-
pCK19-GFP and 22Rv1-pCK19-GFP treated with DNA damag-
ing agents (Mitoxantrone and Cisplatin) and other antimitotic
agents (Vinorelbine) formed colonies, whereas CK19/GFP+ cells
failed to do so (Figure 3G).
Combined Notch and Hedgehog Signaling Inhibition
Depletes Docetaxel-Resistant Prostate Cancer Cells
Given our findings that CK19 cells mediate acquired Docetaxel
resistance in vitro and that these cells were more abundant in
prostate cancer patients treated with Docetaxel, we investigated
whether these cells could be targeted to inhibit acquired resis-
tance to Docetaxel. The upregulation of Notch and Hedgehog
signaling in DU145-DR and 22Rv1-DR (Figure 1) prompted us
to investigate the role of these pathways in the survival of CK
cells. We used shRNAs to knock down genes critical for Notch
and Hedgehog signaling in DU145-pCK19-GFP and 22Rv1-
pCK19-GFP. ShRNAs against NOTCH2, GLI1, and GLI2 were
used in biological replicates conferring a 90% reduction in
protein levels (Figure S4A). NOTCH2 knockdown reduced
the mRNA levels of the Notch target genes HES1 and HEY1,
and GLI1 and GLI2 knockdown reduced the mRNA levels
of the Hedgehog target gene SMO, confirming that knockdown
of these genes disrupted Notch and Hedgehog signaling
(Figure S4B).
We then analyzed the effects of Notch and Hedghehog knock-
down on CK19 cells. Colony formation assays of GFP and
GFP+ sorted DU145-pCK19-GFP and 22Rv1-pCK19-GFP cells
expressing shRNAs against NOTCH2, GLI1, and GLI2 revealed
that individual knockdown of Notch or Hedgehog signaling did
not have an effect on the colony formation of CK19/GFP or
CK19/GFP+ cells (Figure 4A; Figure S4C). In contrast, concomi-
tant knockdown of both pathways dramatically abrogated the
ability of CK19/GFP cells to form colonies, whereas CK19/
GFP+ cells were unaffected (Figure 4A; Figure S4C). These
results indicate that both Notch and Hedgehog signaling path-
ways in combination are required for the maintenance of cells
displaying the Docetaxel-resistant phenotype.
We further validated these findings using the chemical inhibi-
tors Cyclopamine and GDC-0449, Hedgehog pathway antago-
nists that act at the level of Smo (Chen et al., 2002; Karhadkar
et al., 2004; Robarge et al., 2009; Taipale et al., 2000), and
DBZ and Compound E, gamma-secretase inhibitors that blockthological stage in primary prostate cancer tissues.
tate cancer patients (n = 31) with low CK content (%1.3%) compared to high
K cells. Black arrows point to CK cells. Data is represented as means ± SD.
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Figure 3. Docetaxel Exposure Selects for Pre-Existing Resistant Prostate Cancer Cells
(A) Working hypotheses; transition versus enrichment-selection induced by Docetaxel.
(B) Immunofluorescence and flow cytometry quantification of CK18 andCK19 expression in DU145 and 22Rv1.White arrows point to cells with a CK phenotype.
(C) Flow cytometry analysis of DU145-pCK19-GFP and 22Rv1-pCK19-GFP treated with Docetaxel (72 hr).
(D) Colony formation assay and quantification of sorted DU145-pCK19-GFP and 22Rv1-pCK19-GFP cells cultured with Docetaxel, 10 and 50 nM respectively, for
72 hr, or DMSO.
(E) Time-lapse microscopy of DU145-pCK19-GFP treated with Docetaxel. Dotted area shows a CK19/GFP cell.
(F) Immunoblots of GFP and Docetaxel-resistance markers in DU145-pCK19-GFP and 22Rv1-pCK19-GFP sorted cells, as well as in unsorted DU145-pCK19-
GFP and 22Rv1-pCK19-GFP cells exposed to Docetaxel (72 hr) at the same concentrations as in (D).
(G) Colony formation assays and quantification of DU145-pCK19-GFP and 22Rv1-pCK19-GFP sorted cells cultured with or without Mitoxantrone 125 and
500 nM, Cisplatin 5 and 2.5 mM, and Vinorelbine 500 and 750 nM, respectively (all 72 hr). Data is represented asmeans ± SD of triplicate experiments. *p < 0.0001.
See also Figure S3 and Movies S1 and S2.
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2005). Quantitative RT-PCR of pathway target genes confirmed
that these pharmacological inhibitors were targeting their re-
spective pathways (Figure S4D). Flow cytometry analysis of
DU145-pCK19-GFP and 22Rv1-pCK19-GFP cells treated with
a combination of Notch and Hedgehog inhibitors showed a sig-
nificant loss in cell viability of CK19/GFP cells and no effect on
CK19/GFP+ cells (Figure 4B). The decrease in CK19/GFP cell
viability was due to the induction of an apoptotic response, as
demonstrated by Caspase-3 and PARP cleavage (Figure 4C;
Figure S4E). Finally, as observed in the genetic knockdown
studies, colony formation assays confirmed that combined phar-
macological inhibition of Notch and Hedgehog signaling selec-
tively depleted CK19/GFP cells (Figure 4D; Figure S4F).
These results indicated that combined Notch and Hedgehog
inhibition could target CK19 Docetaxel-resistant cells. There-
fore, we hypothesized that a combination strategy of Docetaxel
plus developmental pathway inhibitors could ablate both CK+
and CK compartments. Indeed, flow cytometry analysis of
DU145-pCK19-GFP and 22Rv1-pCK19-GFP revealed that triple
combinations of Cyclopamine and DBZ with Docetaxel reduced
the viability of bothCK19/GFP andCK19/GFP+ cells (Figure 4E).
As expected, triple combination completely ablated the colony
formation capacity of both DU145 and 22Rv1 parental cell lines
(Figure 4F).
Abrogation of Acquired Docetaxel Resistance In Vivo
through Notch and Hedgehog Signaling Inhibition
Wenext evaluated the effects of this combination strategy in vivo.
For these experiments dexamethasone was used as a coadju-
vant therapy to reduce the gut toxicity of gamma-secretase
inhibitors (Real et al., 2009). NOD/SCID mice bearing DU145
and 22Rv1 xenografts were treated with dexamethasone alone,
dual combinations (e.g., dexamethasone plus Docetaxel), triple
combinations (e.g., dexamethasone plus Docetaxel plus DBZ),
or a quadruple combination (dexamethasone plus Docetaxel
plus Cyclopamine plus DBZ). Xenografts treated with dexameth-
asone and Docetaxel temporarily stabilized tumor volume before
progression. Remarkably, mice treated with the quadruple com-
bination showed a robust inhibition of tumor growth during the
course of the experiment (15 weeks), compared to mice under
the other combination regimes, therefore mirroring our in vitro
results (Figure 5A). Inhibitory effects of the drugs on their respec-
tive signaling pathways was confirmed by testing the mRNA
levels of Notch and Hedgehog pathway genes in tumor cells
obtained from xenografts 4 hr after drug administration (Fig-
ure 5B). Moreover, in agreement with our in vitro and human
sample results, Docetaxel treatment of DU145 and 22Rv1 xeno-
grafts enriched for CK cells, and xenografts treated with the
quadruple combination displayed a lower percentage of CK
cells in comparison to Docetaxel-treated animals (Figure 5C).
To control for possible drug toxicity associated with the
quadruple combination, we substitutedDocetaxel for Etoposide,
a chemotherapy agent with minor efficacy in prostate cancer
(Figure S5A). Whereas similar toxicity (% body weight reduction)
was observed (Figure S5B), there was no significant delay in
tumor growth (Figure S5C), indicating that the efficacy of the
quadruple therapy was not a result of drug toxicity. These results
indicated that CK Docetaxel-resistant cells were criticallyCandependent on Notch and Hedgehog signaling, giving the ratio-
nale for an efficacious combination strategy.
Notch and Hedgehog Signaling Regulate Survival
Molecules in Docetaxel-Resistant Cells
Our studies suggested that Notch and Hedgehog signaling were
critical regulators of acquired Docetaxel resistance (Figures 4
and 5). In order to elucidate the molecular mechanisms under-
lying these observations, we investigated the downstream effec-
tors of Notch and Hedgehog signaling in CK19/GFPDocetaxel-
resistant cells. Notch signaling can activate the prosurvival PI3K/
AKT signaling pathway (Meurette et al., 2009; Palomero et al.,
2007), whereas Hedgehog signaling can upregulate the antia-
poptotic molecule Bcl-2 (Dierks et al., 2007; Singh et al., 2010).
Therefore, we speculated that Notch and Hedgehog signaling
may regulate CK19/GFP Docetaxel-resistant cells through pro-
survival and antiapoptotic mechanisms, respectively.
We first examined AKT phosphorylation (Ser473) and Bcl-2
expression in the CK19/GFP and CK19/GFP+ populations of
DU145-pCK19-GFP and 22Rv1-pCK19-GFP. Immunoblots re-
vealed that in both cell lines the CK19/GFP compartment dis-
played increased levels of p-AKT (Ser473) and Bcl-2 (Figure 6A).
To assess whether these survival molecules were indeed regu-
lated by Notch and Hedgehog signaling in CK19/GFP cells,
we performed experiments using chemical inhibitors of Notch
and Hedgehog signaling. Immunoblots showed that inhibition
of Notch signaling and inhibition of Hedgehog signaling signifi-
cantly reduced p-AKT (Ser473) and Bcl-2 levels, respectively
(Figure 6B; Figure S6A).
To determine whether the activity of these downstream effec-
tors was necessary for CK19/GFP cell survival, we tested the
combined effects of LY294002, a selective inhibitor of the
PI3K/AKT pathway (Vlahos et al., 1994), and ABT-737, an inhib-
itor of the Bcl-2 family members (Oltersdorf et al., 2005). These
studies revealed that combined, but not individual, PI3K/AKT
and Bcl-2 inhibition induced apoptosis (Figure 6C) and reduced
colony formation (Figure 6D) in CK19/GFP cells, recapitulating
the effect observed with Notch and Hedgehog inhibitors (see
Figure 4). To further validate the role of Notch and Hedgehog
signaling in CK19/GFP cells through PI3K/AKT and Bcl-2, we
performed rescue experiments. As expected, combined inhibi-
tion of Notch and Hedgehog signaling reduced the viability
and colony formation of CK19/GFP cells, whereas overexpres-
sion of either a constitutively active myristoylated form of AKT
(MYR-AKT) or Bcl-2 reduced the inhibitory effect of these inhib-
itors (Figures 6E and 6F). Interestingly, we further observed that
overexpression of either MYR-AKT or Bcl-2 in the CK19/GFP+
populations of DU145-pCK19-GFP and 22Rv1-pCK19-GFP
was sufficient to confer a multidrug resistant phenotype in
these previously sensitive cells (Figure 6G). This data was con-
sistent with previous reports that overexpression of these mole-
cules contributes to resistance to an array of chemotherapeutics
(Pommier et al., 2004).
Next, we assessed the expression of drug efflux mechanisms
in CK19/GFP cells. Current evidence suggests that the taxane
chemotherapeutics are substrates for p-Glycoprotein/ABCB1
(Gottesman et al., 2002). We observed that P-gp/ABCB1 was
elevated in the CK19/GFP population of 22Rv1-pCK19-GFP
but not DU145-pCK19-GFP (Figure S6B). Consistent with thesecer Cell 22, 373–388, September 11, 2012 ª2012 Elsevier Inc. 379
Figure 4. Docetaxel-Resistant Prostate Cancer Cells Are Dependent on Notch and Hedgehog Signaling
(A) Colony formation assay and quantification of DU145-pCK19-GFP- and 22Rv1-pCK19-GFP-sorted cells expressing shRNAs againstGLI1,GLI2, andNOTCH2
alone, as well as double (GLI1 and GLI2) and triple knockdowns.
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using a Hoechst 33342 assay (Figure S6C). Finally, we observed
that Notch and Hedgehog signaling did not regulate ABCB1
mRNA in 22Rv1-pCK19-GFP cells (Figure S6D). Thus, expres-
sion of this drug efflux molecule was not a consistent feature
of CK19/GFP cells. Taken together, these data suggest that
Notch and Hedgehog signaling regulate the activation of AKT
and expression of Bcl-2, respectively, to promote survival and
multidrug resistance in a P-gp/ABCB1 drug efflux independent
mechanism.
Docetaxel-Resistant Prostate Cancer Cells Have Potent
Tumor-Initiating Capacity
A number of studies have shown that tumor-initiating cells
(T-ICs) may preferentially survive exposure to chemotherapy,
providing an attractive rationale for relapse following initial tumor
shrinkage with standard therapy (Corbin et al., 2011; Ishikawa
et al., 2007; Lonardo et al., 2011; Todaro et al., 2007; Yu et al.,
2007). Having demonstrated that CK cells survive Docetaxel
exposure in vitro and in vivo, we investigated the tumor-initiating
capacity of these cells. Because efficient xenotransplantation is
a major criterion for the validation of a T-IC-enriched compart-
ment (Dalerba et al., 2007; Vermeulen et al., 2008; Visvader
and Lindeman, 2008), we performed serial dilution tumor initia-
tion assays using the Docetaxel-resistant models. Interestingly,
DU145-DR and 22Rv1-DR had higher tumor-initiating capacity
than did their parental sensitive cells when injected into NOD/
SCID IL-2 receptor gamma chain null (NSG) mice (Figure 7A).
These results indicate that DU145 and 22Rv1 Docetaxel-resis-
tant cells display 15.8- and 22.4-fold higher tumor-initiating
capacity than did their parental cells, respectively.
One feature of the Docetaxel-resistance phenotype was lack
of HLAI expression (Figures 1 and 2). Therefore, we reasoned
that viable CK Docetaxel-resistant cells could be isolated
from bulk populations using HLAI expression as a cell surface
marker. Indeed, double marker flow cytometry analysis revealed
that HLAI negativity closely overlapped with the CK population
both in cell lines (Figure S7A) and primary prostate cancers (Fig-
ure S7B). Thus, viable CK and CK+ subpopulations could be
isolated by flow cytometry using HLAI expression.
We next used HLAI as a cell surface marker to perform limiting
dilution tumor initiation assays in NSG mice. These studies re-
vealed that in both DU145 and 22Rv1 the HLAI compartment
was at least 2,000-fold more tumorigenic than the HLAI-positive
compartment (Figure 7B). Furthermore, primary xenografts
formed from HLAI/CK cells recapitulated the phenotypic
heterogeneity of the parental cell lines with an HLAI+/CK+ pheno-
type in the majority of the tumor cells, as well as a small HLAI/(B) Flow cytometry analysis of DU145-pCK19-GFP and 22Rv1-pCK19-GFP treat
(C) Immunoblots of indicated proteins in DU145-pCK19-GFP cells treated with t
(D) Colony formation assay and quantification of DU145-pCK19-GFP-sorted ce
1 mM), alone or in combination (Cyc+DBZ or GDC+CE).
(E) Flow cytometry analysis after Docetaxel (48 hr) alone or in combination with C
GFP cells were treated with 10 and 50 nM Docetaxel, respectively.
(F) Colony formation assay and quantification of parental DU145 and 22Rv1 c
combination with Notch inhibitors (CE or DBZ, both 1 mM) and/or Hedgehog inhib
SD of triplicate experiments. *p < 0.05.
See also Figure S4.
CanCK population that expressed nuclear cleaved Notch2, Gli1,
andGli2, and lacked nuclear AR (Figure 7C; Figure S7C). Further,
HLAI cells isolated from primary xenografts serially engrafted
into secondary recipients, whereas HLAI+ cells rarely engrafted
(Figure 7B). Thus, in both DU145 and 22Rv1, the tumor-initiating
capacity of HLAI cells was2,000-fold higher than HLAI+ cells.
Moreover, we used complement-mediated lysis as an alternative
method to show the presence of an HLAI cell compartment with
high tumor-initiating capacity in the parental cells. Incubation of
DU145 and 22Rv1 parental cells with HLAI antibody and comple-
ment induced a robust depletion of HLAI+ cells, whereas HLAI
cells remained viable (Figure S7D). The surviving HLAI popula-
tion exhibited a higher tumor-initiating capacity in comparison to
the noncomplement depleted cells (Figure S7E).
To investigate the tumorigenic capacity of the identified
prostate T-IC population in fresh tumors, we used primary pros-
tate cancer tissue samples. We confirmed histologically the
presence of adenocarcinoma in the processed tissue in 30
patients (Table S2). Overall, the injection of cells from 4 out of
the 30 (13.3%) confirmed individual prostate cancer samples
generated tumor xenografts after a median follow-up time of
55.6 weeks (range 37.3–62.0) in NOD/SCID mice. Among these
four patient samples, the HLAI cells displayed 336-fold higher
tumorigenic potential compared to the HLAI+ cells (Figure 7D).
Moreover, in a subanalysis using HLAI-sorted cells from primary
xenografts injected into NSG mice, HLAI cells continued to
form tumors efficiently, whereas HLAI+ cells failed to engraft,
indicating that tumor initiation of HLAI cells was independent
of a remnant host immune response (Figure S7F). Immunohisto-
chemistry of tumors derived from HLAI cells showed that they
faithfully reproduced the phenotype of the primary prostate
tumor with the expression of epithelial- and prostate-related
markers (CKs and AR) as well as HLAI antigens in the majority
of tumor cells, in addition to a small HLAI/CK compartment
characterized by lack of AR and expression of nuclear cleaved
Notch2, Gli1, and Gli2 (Figure 7E; Figure S7G). Because of the
long latency of the generated prostate cancer xenografts, we
confirmed their identity by short tandem repeat DNA finger-
printing (data not shown). Further, HLAI cells isolated from
primary xenografts serially engrafted into secondary recipients,
whereas HLAI+ cells failed to engraft (Figure 7D). Taken to-
gether, these results suggest that the HLAI subpopulation is
highly enriched in T-ICs that sustain serial xenotransplantation
and reproduce the phenotypic heterogeneity of the primary
tumor.
Finally, given that our previous data suggested that Notch and
Hedgehog signaling were required to sustain the viability of CK/
HLAI cells, we assessed whether inhibition of these pathwaysed with Cyclopamine (1 mM) and/or DBZ (1 mM, both 48 hr).
he same conditions as (B).
lls exposed for 72 hr to Cyclopamine, GDC-0449, DBZ, and Compound E (all
yclopamine and/or DBZ (both 1 mM). DU145-pCK19-GFP and 22Rv1-pCK19-
ells exposed for 72 hr to Docetaxel (10 and 50 nM, respectively) alone or in
itors (Cyclopamine or GDC-0449, both 1 mM). Data are represented as means ±
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Figure 5. Notch and Hedgehog Inhibition Abrogates the Acquisition of Docetaxel Resistance
(A) Changes in tumor volume of DU145 and 22RV1 xenografts treated with Dexamethasone alone, double combinations, triple combinations, and quadruple
combination. Dose schedules were Dexamethasone (15 mg/kg/i.p. daily), Docetaxel (10 mg/kg/i.p. once a week for 3 weeks every 4 weeks), DBZ (10 mM/kg/ip
daily for 15 days every 4 weeks), and Cyclopamine (50 mg/kg/sc daily).
(B) Quantitative RT-PCR of Notch and Hedgehog target genes in DU145 and 22RV1 xenografts obtained from mice treated with the same drugs and concen-
trations as in (A). Bars represent fold change in mRNA levels relative to vehicle (control).
(C) Microphotographs illustrate the expression of low molecular weight cytokeratins (CK18 and CK19) in DU145 and 22RV1 prostate cancer tumor xenografts in
NOD/SCIDmice treated for 4 weeks with the same drugs as in (A). Magnifications illustrate CK cells. Histogram represents the percentage of CK cells detected
in DU145 and 22RV1 xenografts for each treatment arm. Four xenografts for each treatment groupwhere analyzed. Data is represented asmeans ± SD. *p < 0.05.
See also Figure S5.
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Targeting Docetaxel Resistance in Prostate Cancercould reduce the tumor-initiating capacity of these cells. We
injected 100 HLAI-sorted cells from human prostate cancer
xenografts #5, #9, and #12 subcutaneously into NSG mice,
which were treated with vehicle solution, dexamethasone alone,
dual drug combinations (e.g., dexamethasone plus Cyclop-
amine), or triple drug combination (dexamethasone plus Cyclop-
amine and DBZ). Mice treated with the combination of Notch and
Hedgehog inhibitors showed a significant (p < 0.0001) reduction
in tumor incidence when compared to mice treated with vehicle
solution (DMSO) or each inhibitor alone (Figure 7F).
DISCUSSION
Here, we identify a population of prostate cancer cells, existing
both in cell lines and patient samples, which exhibits resistance
to Docetaxel, an undifferentiated phenotype, dependence on
combined Notch and Hedgehog signaling, and high tumor-initi-
ating capacity. Overall, our results have important implications
for clinical oncology and prostate cancer biology.
Using two independent HRPC cell models, we identified a
Docetaxel-resistance phenotype characterized by absence of
epithelial differentiation markers and HLAI antigens, as well as
activation of developmental pathways. Interestingly, in agree-
ment with our data a previous study reported that treatment
of a breast cancer cell line xenograft with an anthracycline re-
sulted in the loss of CKs and other differentiation markers (Yu
et al., 2007). In vitro studies revealed that the Docetaxel-resis-
tance phenotype corresponds to a small, intrinsically multidrug
resistant subpopulation present in unselected HRPC cells. We
identified a small subpopulation of cells that exhibited the
Docetaxel-resistance phenotype in all primary and metastatic
clinical prostate cancer samples studied, and this cell popula-
tion was significantly higher in metastatic patients treated with
Docetaxel than in untreated patients. Further, the abundance
of cells exhibiting the Docetaxel-resistance phenotype was
higher in metastatic than primary samples, and in primary
untreated samples its percentage was associated with canon-
ical prognostic factors and time to biochemical relapse. Thus,
the Docetaxel-resistance phenotype was consistently identified
in prostate cancer as a small subpopulation, which is associated
with both Docetaxel resistance and canonical prognostic
parameters.
Most importantly, although resistance to Docetaxel in HRPC
has been a subject of considerable interest, the development
of therapeutic strategies that target Docetaxel-resistant cells
has remained an elusive challenge in clinical oncology (MahonFigure 6. Notch and Hedgehog Signaling Regulate Survival Molecules
(A) Immunoblots of indicated proteins in CK19/GFP and CK19/GFP+ sorted cel
(B) Immunoblots of indicated proteins in DU145-pCK19-GFP and 22Rv1-pCK1
(C) Immunoblots of indicated proteins in DU145-pCK19-GFP and 22Rv1-pCK19
(D) Colony formation assay and quantification of colonies derived from GFP an
(E) Flow cytometry analysis after 48 hr administration of Cyclopamine (1 mM) an
transfected with empty vector (EV), MYR-AKT and BCL2. Immunoblots illustrate
(F) Colony formation assay and quantification of DU145-pCK19-GFP- and 22Rv1-
or BCL2 and exposed for 72 hr to Cyclopamine (Cyc), GDC-0449 (GDC), DBZ, a
(G) Colony formation assays and quantifications of GFP+-sorted DU145-pCK19-G
treated for 72 hr with Mitoxantrone 125 and 500 nM, Cisplatin 5 and 2.5 mM, and V
three independent experiments. *p < 0.05.
See also Figure S6.
384 Cancer Cell 22, 373–388, September 11, 2012 ª2012 Elsevier Inet al., 2011; Seruga et al., 2011). Interestingly, Notch and
Hedgehog signaling have been implicated in the self-renewal
and differentiation of progenitor cells as well as prostate cancer
tumorigenesis (Karhadkar et al., 2004; Katoh, 2007; Leong and
Gao, 2008; Wang et al., 2006). The upregulation of Notch and
Hedgehog signaling in our in vitro models prompted us to eval-
uate the role of these pathways in Docetaxel resistance in
HRPC. These studies resulted in a combination strategy that
abrogated tumor regrowth after Docetaxel administration in vivo.
These data corroborate previous studies in other tumor types,
which have found a link between activation of developmental
pathways and chemotherapy resistance (Lonardo et al., 2011;
Meng et al., 2009; Steg et al., 2012). Mechanistically, Notch
and Hedgehog signaling regulated canonical survival molecules
with well-documented roles in chemotherapy resistance (Pom-
mier et al., 2004). These results were consistent with previous
reports that Notch and Hedgehog signaling regulate canonical
survival pathways in other tumor types (Dierks et al., 2007; Meur-
ette et al., 2009; Palomero et al., 2007; Singh et al., 2010). In
summary, given the limited capacity of Docetaxel to control
HRPC, a widespread and fatal disease, this work lays the foun-
dation for a promising therapeutic strategy.
Further, the identified Docetaxel-resistance phenotype en-
abled us to validate a bona fide T-IC population on the basis
of HLAI expression in both HRPC cell lines and primary prostate
clinical samples. The T-IC hypothesis posits that tumors are
hierarchically organized with a distinct compartment endowed
with the capacity to self-renew and generate the diversity of
cells that comprise the tumor, and the gold standard for test-
ing this hypothesis is a serial xenotransplantation assay from
freshly resected human materials (Visvader and Lindeman,
2008; Zhou et al., 2009). Here, we provided evidence that a
subpopulation of cells, which exhibits the Docetaxel-resistance
phenotype in cell lines and prostate cancer tissues, satisfied
the T-IC criteria. These results corroborate a growing body of
evidence (Corbin et al., 2011; Ishikawa et al., 2007; Lonardo
et al., 2011; Todaro et al., 2007; Yu et al., 2007) that T-ICs may
contribute to disease progression by participating in chemo-
therapy resistance.
In conclusion, a common and devastating phenomenon in
clinical oncology is tumor relapse following initial success
with cytotoxic therapies. We provide evidence that inhibition of
Notch and Hedgehog signaling in HRPC depletes a subpopula-
tion of cells responsible for acquired Docetaxel resistance and
tumor initiation, laying the foundation for a promising therapeutic
strategy.in Docetaxel-Resistant Cells
ls from DU145-pCK19-GFP and 22Rv1-pCK19-GFP.
9-GFP cells exposed for 72 hr to DBZ and/or Cyclopamine (both 1 mM).
-GFP cells exposed for 72 hr to LY294002 (50 mM) and/or ABT-737 (10 mM).
d GFP+ cells exposed to the same drugs and concentrations as in (C).
d/or DBZ (1 mM) of DU145-pCK19-GFP and 22Rv1-pCK19-GFP cells stably
the overexpression levels of pAKT (Ser-473) and Bcl-2.
pCK19-GFP-sorted cells stably transfected with empty vector (EV), MYR-AKT,
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Figure 7. Docetaxel-Resistant Prostate Cancer Cells Have High Tumor-Initiating Capacity
(A) Tumor incidence, T-IC frequency, and latencies 36 weeks after injection of limiting dilutions of parental and Docetaxel-resistant cells.
(B) Tumor incidence, T-IC frequency, and latencies 38 weeks after injection of limiting dilutions of DU145 and 22RV1 HLAI-sorted cells.
(C) Image of a mouse bearing tumors after injection of DU145 HLAI cells in the upper flanks and HLAI+ cells in the lower flanks. H&E and immunofluorescence of
indicated proteins in representative tumor xenografts generated from DU145 and 22RV1 HLAI cells. White arrows point to CK cells with positive nuclear
staining of transcription factors and lack of HLAI and AR.
(D) Table summarizes prostate cancer patients’ clinicopathological characteristics, tumor incidence, T-IC frequency, and latencies after 61 weeks of injection of
limiting dilutions of HLAI-sorted cells from fresh human prostate cancer samples.
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Additional experimental procedures are described in detail in the Supple-
mental Experimental Procedures.
Generation of Acquired Docetaxel-Resistant Prostate Cancer Cell
Models
Human HRPC cell lines, DU-145 and 22RV1, were obtained from American
Type Culture Collection (ATCC) and maintained in RPMI 1640 medium
(GIBCO) supplemented with 10% FBS without antibiotics. Docetaxel-resis-
tant clones, DU-145-DR and 22RV1-DR, were selected by culturing cells
with Docetaxel in a dose-escalation manner using 72 hr exposures. Initial
culture was at 5 nM Docetaxel for DU145 and 25 nM for 22RV1. After sensitive
clones were no longer present and surviving DU-145 and 22RV1 cells repopu-
lated the flask, the concentration of Docetaxel was increased to 10, 25, 50,
100, and 250 nM. 22RV1-DR cells were further exposed to 500 nM. The
process of acquired drug resistance took 9 months for DU-145-DR and
6.5 months for 22RV1-DR. In parallel, parental DU-145 and 22RV1 cells
were exposed to DMSO (vehicle solution) in the same dose-escalation
manner. Cell viability, apoptosis, immunoblotting, immunofluorescence, and
quantitative RT-PCR assays are described in the Supplemental Experimental
Procedures.
cDNA Microarray Analysis
22RV1, 22RV1-DR, DU-145, and DU-145-DR gene expression profiles were
analyzed. Total RNA from each sample was isolated by Tryzol (Invitrogen,
Carlsbad, CA, USA) and purified by RNeasy mini kit and RNase-free DNase
set (Qiagen, Venlo, The Netherlands) in accordance with the manufacturer’s
protocols. RNA quality of all samples was tested by RNA electrophoresis
and RNA LabChip analysis (Agilent, Santa Clara, CA, USA) to ensure RNA
integrity. Samples were prepared for analysis with Affymetrix Human U133
arrays in accordance with the manufacturer’s instructions. Gene expression
levels of samples were normalized and analyzed with Microarray Suite,
MicroDB, and Data Mining tool software (Affymetrix, Santa Clara, CA, USA).
The absolute call (present, marginal, or absent) and average difference of
22,215 expressions in a sample, and the absolute call difference, fold change,
average difference of gene expression between two or three samples were
normalized and identified using this software package. Statistical analysis of
the mean expression average difference of genes change was done using
a t test between Docetaxel-sensitive and Docetaxel-resistant samples. Genes
that were not annotated or not easily classified were excluded from the func-
tional clustering analysis.
Gene Ontology Analysis
Genes differentially expressed in the Docetaxel-resistant cells compared to
the parental-sensitive cells generated a list of commonly deregulated tran-
scripts. This list was assessed by the DAVID Bioinformatics Resources,
a web-based statistical hypergeometric test applied for enrichment analysis
of gene ontology (GO) categories, which include biological process, molecular
function, and cellular component (http://david.adcc.ncifcrf.gov/). GO cate-
gories enriched on the highest hierarchical level (Rlevel 5) at statistical signif-
icance (p < 0.01) were taken into consideration.
Generation of the pCK19-GFP Reporter Plasmid
CK19 gene promoter region was amplified from genomic DNA of DU145 cells
by PCR with specific primer sets (Fw 50-AACGCATGCTTTGGGGGGATG-
30and Rv 50-TCCCCCTTTACTCGGCCCCCAC-30) as described previously
(Tripathi et al., 2005). Briefly, a region of 1,768 bp corresponding to human Cy-
tokeratin 19 promoter was amplified. The promoter region includes 1,142 bp of
the 50 UTR region, 480 bp belonging to Exon 1, and 146 bp belonging to Intron(E) H&E and immunofluorescence analysis of indicated proteins in human tumors
represented. White arrows point to CK cells with nuclear expression of transcri
(F) Tumor incidence and latencies 24 weeks after injection of 100 HLAI-sorted
15 mg/kg/i.p. daily, Cyclopamine 50 mg/kg/sc daily plus dexamethasone, DBZ 10
combination. Data is represented as means ± SD. *p < 0.05.
See also Figure S7 and Table S2.
386 Cancer Cell 22, 373–388, September 11, 2012 ª2012 Elsevier In1. The PCR products were digested with Ase l and Hind lll and cloned into
pEGFPN1 vector (Clontech, Mountain View, CA, USA) previously digested
with the same enzymes. As a result, the CMV promoter was removed from
the original vector and the GFP expression was under control of the CK19
promoter. The final construct was confirmed by digestion and sequencing
analysis. DU145 and 22Rv1 cells were transfected with pCK19-GFP construct
using Lipofectamine Plus 2000 (Invitrogen). After 24 hr, medium was replaced
with fresh medium and stably expressing cells selected in the presence of
G418 (Invitrogen). Positive clones were confirmed by direct microscopy and
immunofluorescence and also by PCR amplification of GFP coding region
using specific primers (Fw 50-TTCCTGCGTTATCCCCTGATTC-30 and Rv
50-GCTCCTCCGGCCCTTGCTCACCAT-30). Notch and Hedgehog genetic
(shRNA) and chemical inhibition experiments are described in the Supple-
mental Experimental Procedures.
Live Cell Imaging
Time-lapse videomicroscopy was used to assess Docetaxel sensitivity of
DU145-pCK19-GFP and 22Rv1-pCK19-GFP cells. Cells growing in 6-well
plates at low confluence were placed in the stage inside an incubator
chamber at 37C, 50% humidity and in an atmosphere of 5% CO2. Unat-
tended time-lapse movies of randomly chosen GFP+ and GFP DU145 and
22Rv1 cells were performed with a Nikon Eclipse Ti inverted microscope.
NIS Elements AR (Nikon, Tokyo, Japan) software was used to collect and
process data. Imaging was performed using a 103 objective, and images
were captured using 200-ms exposure times for GFP and 20-ms for bright
field every 30 min.
Human Prostate Cancer Tissue Samples
Formalin-fixed paraffin-embedded human primary (n = 31) and metastatic
(n = 36) prostate cancer tissue samples were provided by the tumor bank
of Columbia University Medical Center. Fresh primary prostate tumor
tissue samples (n = 30) were obtained from patients who had undergone
surgical procedures at Columbia University Medical Center. All samples
were collected under informed consent and supervision of the Columbia
University Medical Center Institutional Review Board, and all studies using
these samples were approved by the Columbia University Medical Center
Institutional Review Board. Tissue sections with cancer were selected by re-
viewing hematoxylin and eosin (H&E) stained slides. Immunohistochemistry
and immunofluorescent analyses are described in the Supplemental Experi-
mental Procedures.
Mouse Procedures
All animal experiments were approved by the Institutional Animal Care
and Use Committee (IACUC) at Columbia University. Animal use and care
was in strict compliance with institutional guidelines and all experiments
conformed to the relevant regulatory standards established by Columbia
University. Xenograft experiments were performed with 5- to 6-week-old
NOD.Cg-Prkdcscid IL2rgtm1Wjl (NSG) and NOD.CB17-Prkdcscid (NOD/SCID)
mice obtained from Jackson Laboratories. In vivo effects of the combination
of Docetaxel with Notch and Hedgehog pathway inhibitors and assessment
of tumor initiating capacity are described in the Supplemental Experimental
Procedures.
Statistical Analyses
Statistical analysis was carried out with SPSS version 19.0 (SPSS, Inc.,
Chicago, IL, USA). Experimental data is expressed as means ± SD and ana-
lyzed by Student’s t test. Association between the percentage of CK cells
and biochemical (PSA) disease recurrence was analyzed by the Kaplan-Meier
method, and curves were compared by the log-rank test. All the statistical
tests were conducted at the two-sided 0.05 level of significance.and primary and secondary xenografts generated from HLAI cells. Patient 9 is
ption factors and lack of HLAI and AR.
cells from prostate cancer xenografts treated with DMSO, Dexamethasone
mM/kg/i.p. daily for 15 days every 4 weeks plus Dexamethasone, or with triple
c.
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